{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:53:45Z","timestamp":1791057225865,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007865","name":"University of Texas Medical Branch at Galveston","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009259","name":"Institute for Translational Sciences, University of Texas Medical Branch","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001439"],"award-info":[{"award-number":["UL1 TR001439"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.amjms.2026.08.019","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:54:26Z","timestamp":1787727266000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness and outcomes of direct oral anticoagulants vs. Vitamin K antagonists (VKA) in atrial arrhythmias patients with isolated lupus anticoagulant without antiphospholipid syndrome: a real-world cohort analysis"],"prefix":"10.1016","author":[{"given":"Omar","family":"Obeidat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith","family":"Alhuneafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed F","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Elbanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al-abdouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Alrifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deaa","family":"Abu Jazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alsadawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"Khalife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukaila","family":"Raji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiham","family":"Albaeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjms.2026.08.019_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.019_bib0002","first-page":"1","article-title":"Decoding the evidence: a synopsis of indications and evidence for catheter ablation in atrial fibrillation (Review)","volume":"5","author":"Obeidat","year":"2024","journal-title":"Med Int (Lond)"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.019_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s41999-021-00537-w","article-title":"Atrial fibrillation: a geriatric perspective on the 2020 ESC guidelines","volume":"13","author":"Polidori","year":"2022","journal-title":"Eur Geriatr Med"},{"key":"10.1016\/j.amjms.2026.08.019_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1352734","article-title":"Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors","volume":"11","author":"Kumar","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.amjms.2026.08.019_bib0005","first-page":"1503","article-title":"The multiple causes of stroke in atrial fibrillation: thinking broadly","volume":"34","author":"D'Souza","year":"2018","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.019_bib0006","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12916-017-0807-7","article-title":"Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant","volume":"15","author":"Posch","year":"2017","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.amjms.2026.08.019_bib0007","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.amjms.2026.08.019_bib0008","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","article-title":"Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the ISTH","volume":"18","author":"Tripodi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.amjms.2026.08.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12676","article-title":"Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants","volume":"6","author":"Favaloro","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.amjms.2026.08.019_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines","volume":"8","author":"Pastori","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.019_bib0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.amjms.2026.08.019_bib0012","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.15158","article-title":"Trial of Rivaroxaban in AntiPhospholipid syndrome (TRAPS): two-year outcomes after the study closure","volume":"19","author":"Pengo","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"13","key":"10.1016\/j.amjms.2026.08.019_bib0013","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2026.08.019_bib0014","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.amjms.2026.08.019_bib0015","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.amjms.2026.08.019_bib0016","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"9921","key":"10.1016\/j.amjms.2026.08.019_bib0017","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.amjms.2026.08.019_bib0018","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.amjms.2026.08.019_bib0019","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjms.2026.08.019_bib0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjms.2026.08.019_bib0021","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","article-title":"Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the ENGAGE AF-TIMI 48 study","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.amjms.2026.08.019_bib0022","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.amjmed.2016.02.028","article-title":"Mortality in patients with atrial fibrillation randomized to Edoxaban or Warfarin: insights from the ENGAGE AF-TIMI 48 trial","volume":"129","author":"Giugliano","year":"2016","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.amjms.2026.08.019_bib0023","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/jth.13139","article-title":"Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Chai-Adisaksopha","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.amjms.2026.08.019_bib0024","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","article-title":"Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants","volume":"17","author":"Dufrost","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.amjms.2026.08.019_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2024.03.013","article-title":"Thrombosis recurrence in single antiphospholipid antibody-positive patients: implications for classification and management","volume":"237","author":"Bakow","year":"2024","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.amjms.2026.08.019_bib0026","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.amjms.2026.08.019_bib0027","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.amjms.2026.08.019_bib0028","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.amjms.2026.08.019_bib0029","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1538-7836.2009.03446.x","article-title":"Lupus anticoagulants and anti-phospholipid antibodies as risk factors for a first episode of ischemic stroke","volume":"7","author":"Saidi","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.amjms.2026.08.019_bib0030","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1161\/STROKEAHA.120.030431","article-title":"Antiphospholipid antibody and recurrent ischemic stroke: a systematic review and meta-analysis","volume":"51","author":"Kim","year":"2020","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.amjms.2026.08.019_bib0031","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/FJC.0000000000001578","article-title":"Apixaban versus vitamin K antagonists in patients with antiphospholipid syndrome: a cohort study","volume":"84","author":"Sikorska","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"issue":"36","key":"10.1016\/j.amjms.2026.08.019_bib0032","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2024.39.e252","article-title":"Direct oral anticoagulants in antiphospholipid syndrome-associated venous thromboembolism: real world evidence","volume":"39","author":"Hwang","year":"2024","journal-title":"J Korean Med Sci"},{"issue":"13","key":"10.1016\/j.amjms.2026.08.019_bib0033","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.3390\/jcm13133784","article-title":"Direct oral anticoagulants versus warfarin in obese patients with atrial fibrillation and venous thromboembolism","volume":"13","author":"Karakasis","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjms.2026.08.019_bib0034","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/0115701611330090250130075810","article-title":"Direct oral anticoagulants versus vitamin K antagonists in morbidly obese anticoagulated patients","volume":"23","author":"Sagris","year":"2025","journal-title":"Curr Vasc Pharmacol"},{"issue":"2","key":"10.1016\/j.amjms.2026.08.019_bib0035","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ehf2.15128","article-title":"eGFR slope as predictor of mortality in heart failure patients","volume":"12","author":"Verstreken","year":"2025","journal-title":"ESC Heart Fail"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962926003514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962926003514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:28:36Z","timestamp":1791055716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962926003514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"alternative-id":["S0002962926003514"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2026.08.019","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and outcomes of direct oral anticoagulants vs. Vitamin K antagonists (VKA) in atrial arrhythmias patients with isolated lupus anticoagulant without antiphospholipid syndrome: a real-world cohort analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2026.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}